Phase III ANNOUNCE study of Lartruvo fails to meet endpoint in soft tissue sarcoma.- Eli Lilly
Eli Lilly reported that the results of ANNOUNCE, the Phase III study of Lartruvo (olaratumab), in combination with doxorubicin in patients with advanced or metastatic soft tissue sarcoma (STS), did not confirm the clinical benefit of Lartruvo in combination with doxorubicin as compared to doxorubicin, a standard of care treatment. Specifically, the study did not meet the primary endpoints of overall survival (OS) in the full study population or in the leiomyosarcoma (LMS) sub-population; there was no difference in survival between the study arms for either population. Lartruvo was well tolerated; there were no new safety signals identified and the safety profile was comparable between treatment arms. Lilly plans to present the ANNOUNCE data at an upcoming medical conference and will publish the results in a medical journal.
Comment: Lartruvo in combination with doxorubicin previously showed an OS benefit in STS in a 133-patient, U.S.-only, randomized Phase II trial, which led to accelerated approval by the FDA and conditional marketing authorization by the EMA. Continued approval is contingent upon verification of clinical benefit in a confirmatory trial. As ANNOUNCE did not confirm clinical benefit, Lilly is working with global regulators to determine the appropriate next steps for Lartruvo.
While these discussions are ongoing, patients who are currently receiving Lartruvo may, in consultation with their physician, continue their course of therapy if they are receiving clinical benefit. For patients who have not previously received Lartruvo, the results of the Phase III trial do not support initiating treatment with Lartruvo in patients with STS, outside of participation in a clinical trial. At this time, Lilly is suspending promotion of Lartruvo.
Related news and insights
AbbVie has announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of risankizumab (Skyrizi 150 mg, subcutaneous injection at week 0, week 4 and every 12 weeks thereafter) alone or in combination with methotrexate (MTX), for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).
Merck Inc., announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine) for active immunization for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older. The CHMP recommendation will now be reviewed by the European Commission for marketing authorization in the European Union, and a final decision is expected by the end of the year.
Merck Inc., and Eisai announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted positive opinions recommending approval of the combination of Keytruda, Merck’s anti-PD-1 therapy, plus Lenvima (marketed as Kisplyx in the European Union [EU]) for the treatment of advanced renal cell carcinoma [RCC]), the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, for two different indications.